|
CLOCK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.38469999700197E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.35599999965208E-07 |
| Normal-vs-Stage2 |
1.247120E-04 |
| Normal-vs-Stage3 |
4.23290000051146E-07 |
| Normal-vs-Stage4 |
3.810600E-04 |
| Stage1-vs-Stage2 |
8.039200E-01 |
| Stage1-vs-Stage3 |
3.356800E-01 |
| Stage1-vs-Stage4 |
9.173000E-01 |
| Stage2-vs-Stage3 |
6.653400E-01 |
| Stage2-vs-Stage4 |
9.120200E-01 |
| Stage3-vs-Stage4 |
5.824000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.2997999998543E-07 |
| Normal-vs-AfricanAmerican |
3.156400E-02 |
| Normal-vs-Asian |
8.93980000027383E-07 |
| Caucasian-vs-AfricanAmerican |
2.865800E-01 |
| Caucasian-vs-Asian |
2.399400E-01 |
| AfricanAmerican-vs-Asian |
9.327800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.70160002649556E-09 |
| Normal-vs-Female |
1.26450000004219E-06 |
| Male-vs-Female |
6.632200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.69406999999122E-05 |
| Normal-vs-Age(41-60Yrs) |
5.80799999982951E-07 |
| Normal-vs-Age(61-80Yrs) |
1.13180000005375E-06 |
| Normal-vs-Age(81-100Yrs) |
1.119930E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.359400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.360800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.722400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.406000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.034400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.432600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.734300E-02 |
| Classical-VS-Follicular |
3.669200E-01 |
| Classical-VS-Other |
9.102300E-02 |
| Classical-VS-Normal |
2.297200000001E-06 |
| Tall-VS-Follicular |
2.877000E-01 |
| Tall-VS-Other |
2.277800E-01 |
| Tall-VS-Normal |
6.96399999999819E-07 |
| Follicular-VS-Other |
1.946850E-01 |
| Follicular-VS-Normal |
1.99506999999377E-05 |
| Other-VS-Normal |
1.300780E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.89600000144452E-08 |
| Normal-vs-N1 |
1.213140E-04 |
| N0-vs-N1 |
9.803000E-01 |
|
|
